APA

Verma A., Chopra A., Lee Y. W., Bharwani L. D., Asmat A. B., Aneez D. B. A., Akbar F. A., Lim A. Y. H., Chotirmall S. H. & Abisheganaden J. (20171003). Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma. : Current drug discovery technologies.

Chicago

Verma Akash, Chopra Akhil, Lee Yeo W, Bharwani Lavina D, Asmat Atasha B, Aneez Dokeu B A, Akbar Fazuludeen A, Lim Albert Y H, Chotirmall Sanjay H and Abisheganaden John. 20171003. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma. : Current drug discovery technologies.

Harvard

Verma A., Chopra A., Lee Y. W., Bharwani L. D., Asmat A. B., Aneez D. B. A., Akbar F. A., Lim A. Y. H., Chotirmall S. H. and Abisheganaden J. (20171003). Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma. : Current drug discovery technologies.

MLA

Verma Akash, Chopra Akhil, Lee Yeo W, Bharwani Lavina D, Asmat Atasha B, Aneez Dokeu B A, Akbar Fazuludeen A, Lim Albert Y H, Chotirmall Sanjay H and Abisheganaden John. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma. : Current drug discovery technologies. 20171003.